Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why?

Although anti-CD19 chimeric antigen receptor (CAR) T-cell therapy shows good efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), it fails to improve long-term leukemia-free survival (LFS). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) after...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Huiwen, Hu, Yu, Mei, Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687790/
https://www.ncbi.nlm.nih.gov/pubmed/33292685
http://dx.doi.org/10.1186/s40364-020-00247-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687790/
https://www.ncbi.nlm.nih.gov/pubmed/33292685
http://dx.doi.org/10.1186/s40364-020-00247-8

Ejemplares similares